Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

Completed · Phase 4

Conditions studied: Hyperglycemia, Acute Coronary Syndromes, Myocardial Infarction

In brief

The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

Key facts

Study ID

NCT00736229

Run by

Saint Luke's Health System

People needed

40

Starts

2008-08-01

Expected to finish

2012-08-01

Last updated by the study team

2014-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Admission to coronary ICU
• Admission blood glucose 140-299 mg/dL
• Primary cardiovascular diagnosis by attending physician
• Under primary care of cardiology service
• Age > 18 years old
• Ventilator independent
• Able to provide informed consent

You may not qualify if…

• Admission blood glucose < 140 or > 300 mg/dL
• Ventilator dependent
• Unconscious sedation
• Type 1 diabetes
• Known pregnancy
• Admitted to coronary ICU for right heart cath to measure hemodynamics prior to transplant
• Post transplant procedure
• Currently enrolled in another clinical trial
• Unable to provide informed consent
• Creatinine clearance < 30 mL/min
• On insulin treatment except for monotherapy with long-acting basal insulin (e.g., insulin glargine [Lantus®] or detemir [Levemir®])
• Gastroparesis

Where it is running

• Mid America Heart Institute Saint Luke's Health System — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.